Lonza, a Basel, Switzerland-based manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, acquired Synaffix, an Amsterdam, The Netherlands-based biotechnology company focused on commercializing its clinical-stage technology platform for the development of ADCs.
The acquisition comprises an initial financial consideration of €100 million in cash and up to €60 million in additional performance-based consideration
The acquisition will further strengthen Lonza’s bioconjugates offering through the integration of Synaffix’ proprietary platform and R&D capabilities, including payload and site-specific linker technology.
Led by CEO Peter van de Sande, Synaffix is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy). The platform, which comprises proprietary GlycoConnect™, HydraSpace™ and toxSYN™ technologies that can considerably enhance the efficacy and tolerability of ADCs, is commercially validated by well over $1.0 billion in technology out-licensing deals with partners including ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin.
Lonza and Synaffix will continue to expand their Center of Excellence for bioconjugate technology development, with a focus on out-licensing bioconjugates technologies for cytotoxic ADCs, targeted gene therapy, immune cell engagers applications and beyond. As a Lonza company, Synaffix will continue to operate under the Synaffix name and further expand its operations in Oss (NL) to cater for further innovation and growth.
Lonza helps its customers to deliver new and innovative medicines that help treat a wide range of diseases by combining technological insight with manufacturing, scientific expertise and process approach.
FinSMEs
01/06/2023